Market Place
Sourcing Support
Calliditas To Present Four Abstracts At ASN Kidney Week 2024
16 Oct 2024 //
GLOBENEWSWIRE
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
16 Sep 2024 //
PR NEWSWIRE
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
03 Sep 2024 //
PR NEWSWIRE
Calliditas Therapeutics Takes Corporate Actions Post Asahi Kasei News
03 Sep 2024 //
PR NEWSWIRE
Calliditas Interim Report January to June 2024
12 Aug 2024 //
PR NEWSWIRE
Invitation to the presentation of Calliditas´s interim report January - June
05 Aug 2024 //
PR NEWSWIRE
Calliditas Therapeutics To Attend 2024 WIN Leadership Conference
01 Aug 2024 //
GLOBENEWSWIRE
Number of shares and votes in Calliditas Therapeutics
31 Jul 2024 //
PR NEWSWIRE
Calliditas` Redesigned Liver Disease Trial Hits Primary Endpoint
26 Jul 2024 //
FIERCE BIOTECH
Calliditas Reports Positive Phase 2b Data In Primary Biliary Cholangitis
26 Jul 2024 //
PR NEWSWIRE
Calliditas Partner STADA Receives EU Approval For Kinpeygo In IgA Nephropathy
26 Jul 2024 //
PR NEWSWIRE
Calliditas’ partner Viatris for phase III clinical trial with Nefecon in Japan
05 Jul 2024 //
PHARMABIZ
Calliditas Provides Setanaxib Patent Update
18 Jun 2024 //
PR NEWSWIRE
Bulletin From Annual General Meeting Of Calliditas Therapeutics
17 Jun 2024 //
PR NEWSWIRE
Calliditas Partner STADA Gets CHMP Nod For Kinpeygo In IgA Nephropathy
31 May 2024 //
PR NEWSWIRE
Asahi Kasei moves to buy Calliditas for more than $1B
29 May 2024 //
FIERCE PHARMA
Asahi Kasei: Acquiring Calliditas To Grow As Global Healthcare Company
28 May 2024 //
BUSINESSWIRE
Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billion
28 May 2024 //
REUTERS
Calliditas Q1 report, January - March 2024
23 May 2024 //
PR NEWSWIRE
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
15 May 2024 //
PR NEWSWIRE
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
15 May 2024 //
PR NEWSWIRE
Calliditas announces positive topline results from phase 2 , setanaxib
07 May 2024 //
PHARMABIZ
Calliditas: Positive Phase 2 Head/Neck Cancer Data For NOX Inhibitor
06 May 2024 //
PR NEWSWIRE
Calliditas Therapeutics` 2023 Annual Report Published
24 Apr 2024 //
PR NEWSWIRE
Calliditas Presents Nefecon Phase 3 IgA Nephropathy Analyses
18 Apr 2024 //
PR NEWSWIRE
Calliditas Therapeutics to Attend Conferences in April
09 Apr 2024 //
PR NEWSWIRE
Calliditas Receives Notice of Allowance for US Patent Covering Setanaxib
08 Apr 2024 //
PR NEWSWIRE
Calliditas to Present Nefecon Data at the ISN World Congress
08 Apr 2024 //
PR NEWSWIRE
Calliditas’ setanaxib to receive US patent “Use of NOX Inhibitors for Cancer”
08 Apr 2024 //
PHARMABIZ
Calliditas announces an seven year orphan drug exclusivity period for TARPEYO®
06 Mar 2024 //
PR NEWSWIRE
Calliditas Therapeutics to Attend Investor Conferences in March
01 Mar 2024 //
PR NEWSWIRE
Calliditas Year-end report, January - December 2023
21 Feb 2024 //
PR NEWSWIRE
Invitation to the presentation of Calliditas´ Year-end report 2023
14 Feb 2024 //
PR NEWSWIRE
Calliditas provides patent update
13 Feb 2024 //
PR NEWSWIRE
Calliditas Therapeutics provides business update ahead of JP Morgan conference
08 Jan 2024 //
PR NEWSWIRE
Calliditas to present at JP Morgan Healthcare Conference
07 Jan 2024 //
PR NEWSWIRE
Calliditas Therapeutics appoints Maria Törnsén as President North America
07 Jan 2024 //
PR NEWSWIRE
FDA grants Calliditas full nod for kidney disease drug Tarpeyo
21 Dec 2023 //
FIERCE PHARMA
Calliditas Receives Notice of Allowance for Patent Application Covering TARPEYO
11 Dec 2023 //
PR NEWSWIRE
Calliditas announces additions to the management team
01 Dec 2023 //
PR NEWSWIRE
Calliditas Presents Data from the NefIgArd Phase 3 trial at IIgANN Tokyo 2023
29 Sep 2023 //
PR NEWSWIRE
STADA & Calliditas announce filing for full marketing authorization of Kinpeygo
28 Sep 2023 //
PR NEWSWIRE
FDA grants priority review for full approval of TARPEYO for IgA Nephropathy
18 Aug 2023 //
PR NEWSWIRE
Interim Report Q2, 2023: Calliditas Therapeutics
17 Aug 2023 //
PR NEWSWIRE
Calliditas announces supportive interim data from Phase 2 trial with setanaxib
13 Jul 2023 //
PR NEWSWIRE
Calliditas Therapeutics Submits sNDA to U.S. FDA for Full Approval of TARPEYO®
21 Jun 2023 //
PR NEWSWIRE
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
30 May 2023 //
PR NEWSWIRE
Calliditas Therapeutics: Interim Report Q1, 2023
16 May 2023 //
PR NEWSWIRE
Calliditas Therapeutics` 2022 Annual Report Published
26 Apr 2023 //
PR NEWSWIRE
Calliditas Announces Publication of Cost-Effectiveness Analysis of Nefecon
11 Apr 2023 //
GLOBENEWSWIRE
Calliditas to participate in upcoming investor conferences
31 Mar 2023 //
PR NEWSWIRE
Calliditas Reports Positive Topline Results from Phase 3 NefIgArd Trial
13 Mar 2023 //
PR NEWSWIRE
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial
12 Mar 2023 //
PR NEWSWIRE
Calliditas - Year-End Report, 2022
23 Feb 2023 //
PR NEWSWIRE
Calliditas Receives Conditional Marketing Authorization from MHRA for Kinpeygo
02 Feb 2023 //
PR NEWSWIRE
Number of shares and votes in Calliditas Therapeutics
31 Jan 2023 //
PR NEWSWIRE
Calliditas CEO acquires shares through the exercise of Calliditas
20 Dec 2022 //
PR NEWSWIRE
Calliditas announces agreement with Viatris to commercialize specialty therapy
13 Dec 2022 //
PRNEWSWIRE
Calliditas` partner Everest`s NDA for Nefecon is accepted by the NMPA
16 Nov 2022 //
PRNEWSWIRE
Calliditas Therapeutics: Interim Report Q3, 2022
14 Nov 2022 //
PRNEWSWIRE
